Rituximab and infliximab desensitization with anti-IgE mAb omalizumab as adjuvant therapy: a case series

J Allergy Clin Immunol Pract. 2022 Dec;10(12):3317-3319. doi: 10.1016/j.jaip.2022.08.036. Epub 2022 Sep 8.

Authors

Margherita Perlato¹, Valentina Mecheri¹, Matteo Accinno¹, Emanuele Vivarelli², Andrea Matucci³, Alessandra Vultaggio²

Affiliations

¹ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
² Immunoallergology Unit, Careggi University Hospital, Florence, Italy.
³ Immunoallergology Unit, Careggi University Hospital, Florence, Italy. Electronic address: andrea.matucci@unifi.it.

PMID: 36087862
DOI: 10.1016/j.jaip.2022.08.036

No abstract available

MeSH terms

Anti-Allergic Agents*
Humans
Immunosuppressive Agents
Infliximab / therapeutic use
Omalizumab* / therapeutic use
Rituximab / therapeutic use

Substances

Omalizumab
Infliximab
anti-IgE antibodies
Rituximab
Immunosuppressive Agents
Anti-Allergic Agents